Expert Perspectives on Key Results From ICONIC-ADVANCE 1 and 2 Trials

Patients participating in head-to-head clinical trials between icotrokinra and deucravacitinib experienced superior outcomes with the oral IL-23 receptor blocker across multiple efficacy measures. The ICONIC-ADVANCE studies enrolled adults with moderate to severe plaque psoriasis, comparing the new oral peptide against both placebo and the established TYK2 inhibitor. Patients showed consistent, reproducible responses favoring icotrokinra, with separation evident early in treatment and maintained throughout the 24-week study period.

Clinical trial participants achieved remarkable response rates with icotrokinra, including double the complete skin clearance rates compared with deucravacitinib when measuring the highest treatment bar of PASI 100 or IGA 0. Patients receiving icotrokinra demonstrated superior depth of response, with the greatest separation between treatments observed at the most stringent efficacy end points. These results represent unprecedented achievement for patients receiving oral psoriasis treatment, approaching efficacy levels typically associated with the most effective biologic therapies.

Patient safety data revealed reassuring profiles for icotrokinra, with side effects similar to placebo and lower adverse event rates compared with deucravacitinib. Infection rates were actually lower in patients receiving icotrokinra, whereas expected adverse events associated with deucravacitinib (including acne and herpes) occurred as anticipated. Patients experienced well-tolerated treatment with the oral IL-23 receptor blocker, providing confidence for individuals with moderate to severe psoriasis requiring effective oral therapy options with favorable safety characteristics.